Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS

 (PCA)

37
Delayed Quote. Delayed Euronext Paris - 05/17 11:29:18 am
3.41 EUR   --.--%
04/23 PCAS: quarterly financial information as of March 31, 2013
04/11 PCAS: proposed merger between PCAS and Dynaction
03/20 PCAS: sale of SBS
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Latest news on PCAS
04/23 PCAS: quarterly financial information as of March 31, 2013
04/11 PCAS: proposed merger between PCAS and Dynaction
03/20 PCAS: sale of SBS
02/20 PCAS: Strong earnings growth in 2012, Sale of SBS
01/24 PCAS: 2012 net sales
2012 PCAS: Quarterly financial information at september 30th, 2012
2012 PCAS: Business buoyant over the first half of 2012 - Strong growth in results
2012 PCAS: 2012 First-half sales
2012 PCAS: expands US office
2012 PCAS: Quarterly Financial Information as of March 31st 2012
2012 PCAS: 2011 results
2012 PCAS: 2011 sales
2012 PCAS: Clinigen and PCAS sign long-term supply agreement
2012 PCAS: and Clinigen sign long-term supply agreement for the production of Foscav..
2012 PCAS: La production du principe actif : un levier stratégique pour optimiser le..
2011 PCAS: Extension of the manufacturing between VLG Chem and Sanofi
2011 PCAS: Extension of the manufacturing contract between VLG Chem and Sanofi until..
2011 PCAS: New U.S. Patent for Directed Evolution technology Granted to Proteus
2011 PCAS: quarterly financial reporting Sep 30, 2011
2011 PCAS: 2011 half-year results
2011 PCAS: Results of the bondholders vote on the resolutions presented at the Gener..
2011 PCAS: 2011 first-half sales
2011 PCAS: debt restructured
2011 PCAS: 1st quarter 2011 financial reporting
2011 PCAS: Governance: pcas strengthens itself
2011 PCAS: 2010 earnings
Advertisement
Chart
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Income Statement Evolution
PCAS : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.